Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection

Ishfaq Bhat, Sandeep Mukherjee

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

An estimated 180 million people worldwide are infected with hepatitis C virus (HCV). HCV is the most common blood borne infection in the United States with a prevalence nearly 4 fold greater than human immunodeficiency virus (HIV). It is the leading cause of end stage liver disease, hepatocellular carcinoma and liver transplantations in the United States. Hepatitis B virus (HBV)) and HCV are common among patients with HIV because of shared routes of viral transmission. Due to successful highly active antiretroviral therapy, opportunistic infections and related complications from Acquired Immune Deficiency Syndrome (AIDS) are less common causes of mortality in HIV patients. However, endstage liver disease due to chronic HBV and HCV infection is becoming a leading cause of death among persons with HIV infection worldwide with the risk of death due to liver disease is inversely related to the CD4 cell count.There has been a strong debate recently about the need for aggressive evaluation of co-infected patients with end stage liver disease for liver transplantation. This chapter will review the outcomes of liver transplantation for co-infected patients, important drug interactions and briefly discuss the ethical issues related to this vulnerable population/.

Original languageEnglish (US)
Title of host publicationHepatitis C and Liver Transplantation
PublisherNova Science Publishers, Inc.
Pages218-228
Number of pages11
ISBN (Electronic)9781617611346
ISBN (Print)9781617286162
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Coinfection
Hepacivirus
Liver Transplantation
Hepatitis
HIV
End Stage Liver Disease
Virus Diseases
Hepatitis B virus
Liver Diseases
Opportunistic Infections
Highly Active Antiretroviral Therapy
Chronic Hepatitis B
Vulnerable Populations
CD4 Lymphocyte Count
Drug Interactions
Ethics
Cause of Death
Hepatocellular Carcinoma
Acquired Immunodeficiency Syndrome
Mortality

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Bhat, I., & Mukherjee, S. (2010). Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection. In Hepatitis C and Liver Transplantation (pp. 218-228). Nova Science Publishers, Inc..

Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection. / Bhat, Ishfaq; Mukherjee, Sandeep.

Hepatitis C and Liver Transplantation. Nova Science Publishers, Inc., 2010. p. 218-228.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bhat, I & Mukherjee, S 2010, Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection. in Hepatitis C and Liver Transplantation. Nova Science Publishers, Inc., pp. 218-228.
Bhat I, Mukherjee S. Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection. In Hepatitis C and Liver Transplantation. Nova Science Publishers, Inc. 2010. p. 218-228
Bhat, Ishfaq ; Mukherjee, Sandeep. / Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection. Hepatitis C and Liver Transplantation. Nova Science Publishers, Inc., 2010. pp. 218-228
@inbook{689b87197e334fa598cf224e23f3b2b3,
title = "Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection",
abstract = "An estimated 180 million people worldwide are infected with hepatitis C virus (HCV). HCV is the most common blood borne infection in the United States with a prevalence nearly 4 fold greater than human immunodeficiency virus (HIV). It is the leading cause of end stage liver disease, hepatocellular carcinoma and liver transplantations in the United States. Hepatitis B virus (HBV)) and HCV are common among patients with HIV because of shared routes of viral transmission. Due to successful highly active antiretroviral therapy, opportunistic infections and related complications from Acquired Immune Deficiency Syndrome (AIDS) are less common causes of mortality in HIV patients. However, endstage liver disease due to chronic HBV and HCV infection is becoming a leading cause of death among persons with HIV infection worldwide with the risk of death due to liver disease is inversely related to the CD4 cell count.There has been a strong debate recently about the need for aggressive evaluation of co-infected patients with end stage liver disease for liver transplantation. This chapter will review the outcomes of liver transplantation for co-infected patients, important drug interactions and briefly discuss the ethical issues related to this vulnerable population/.",
author = "Ishfaq Bhat and Sandeep Mukherjee",
year = "2010",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781617286162",
pages = "218--228",
booktitle = "Hepatitis C and Liver Transplantation",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Evaluation and outcomes of liver transplantation for hepatitis/hiv co-infection

AU - Bhat, Ishfaq

AU - Mukherjee, Sandeep

PY - 2010/1/1

Y1 - 2010/1/1

N2 - An estimated 180 million people worldwide are infected with hepatitis C virus (HCV). HCV is the most common blood borne infection in the United States with a prevalence nearly 4 fold greater than human immunodeficiency virus (HIV). It is the leading cause of end stage liver disease, hepatocellular carcinoma and liver transplantations in the United States. Hepatitis B virus (HBV)) and HCV are common among patients with HIV because of shared routes of viral transmission. Due to successful highly active antiretroviral therapy, opportunistic infections and related complications from Acquired Immune Deficiency Syndrome (AIDS) are less common causes of mortality in HIV patients. However, endstage liver disease due to chronic HBV and HCV infection is becoming a leading cause of death among persons with HIV infection worldwide with the risk of death due to liver disease is inversely related to the CD4 cell count.There has been a strong debate recently about the need for aggressive evaluation of co-infected patients with end stage liver disease for liver transplantation. This chapter will review the outcomes of liver transplantation for co-infected patients, important drug interactions and briefly discuss the ethical issues related to this vulnerable population/.

AB - An estimated 180 million people worldwide are infected with hepatitis C virus (HCV). HCV is the most common blood borne infection in the United States with a prevalence nearly 4 fold greater than human immunodeficiency virus (HIV). It is the leading cause of end stage liver disease, hepatocellular carcinoma and liver transplantations in the United States. Hepatitis B virus (HBV)) and HCV are common among patients with HIV because of shared routes of viral transmission. Due to successful highly active antiretroviral therapy, opportunistic infections and related complications from Acquired Immune Deficiency Syndrome (AIDS) are less common causes of mortality in HIV patients. However, endstage liver disease due to chronic HBV and HCV infection is becoming a leading cause of death among persons with HIV infection worldwide with the risk of death due to liver disease is inversely related to the CD4 cell count.There has been a strong debate recently about the need for aggressive evaluation of co-infected patients with end stage liver disease for liver transplantation. This chapter will review the outcomes of liver transplantation for co-infected patients, important drug interactions and briefly discuss the ethical issues related to this vulnerable population/.

UR - http://www.scopus.com/inward/record.url?scp=85026511022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026511022&partnerID=8YFLogxK

M3 - Chapter

SN - 9781617286162

SP - 218

EP - 228

BT - Hepatitis C and Liver Transplantation

PB - Nova Science Publishers, Inc.

ER -